<p>加利福尼亞州帕洛阿爾託 --（商業資訊）--Guardant Health, Inc.（納斯達克：GH），一家領先的精準腫瘤學公司，今天宣佈，Guardant 董事會的薪酬委員會於 2026 年 4 月 21 日批准向 267 名新非執行員工授予代表 143,898 股普通股的限制性股票單位（“RSUs”），授予日期為 2026 年 5 月 11 日，依據 Guardant Health, Inc. 2023 年就業誘導激勵獎勵計劃（“誘導計劃”）。這些 RSUs 作為員工與 Guardant 簽訂僱傭合同的重要誘因，符合納斯達克上市規則 5635(c)(4)。</p>
<p>誘導計劃專門用於向之前未曾是 Guardant 員工的個人授予股權獎勵，或在經過真實的非僱傭期後，作為這些個人與 Guardant 簽訂僱傭合同的重要誘因，依據納斯達克上市規則 5635(c)(4)。</p>
<p>每個 RSU 獎勵所對應的股份三分之一將在每年授予開始日期的週年日按年歸屬，前提是每位員工在每個歸屬日期仍繼續在 Guardant 工作。這些 RSUs 受誘導計劃的條款和條件以及涵蓋該授予的 RSU 獎勵協議的條款和條件的約束。</p>
<p><strong>關於 Guardant Health</strong></p>
<p>Guardant Health 是一家領先的精準腫瘤學公司，專注於保護健康，讓每個人都能擁有更多無癌的時間。Guardant 成立於 2012 年，通過提供對疾病驅動因素的關鍵洞察，利用其先進的血液和組織檢測、真實世界數據和人工智能分析，正在改變患者護理並加速新的癌症療法。Guardant 的檢測有助於改善各個階段的護理結果，包括早期篩查癌症、監測早期癌症的復發以及為晚期癌症患者選擇治療方案。有關更多信息，請訪問 guardanthealth.com，並在 LinkedIn、X（推特）和 Facebook 上關注該公司。</p>
<p><strong>Guardant Health 前瞻性聲明</strong></p>
<p>本新聞稿包含根據聯邦證券法的定義的前瞻性聲明，包括關於 Guardant Health 的液體活檢測試或檢測的潛在用途、價值、益處和優勢的聲明，這些聲明涉及風險和不確定性，可能導致實際結果與這些前瞻性聲明中表達的預期結果和期望存在重大差異。這些聲明基於當前的期望、預測和假設，實際結果可能因多種因素而與這些聲明存在重大差異。這些以及可能影響 Guardant Health 財務和運營結果的其他風險和不確定性，以及導致實際結果與本新聞稿中所作的前瞻性聲明所指示的結果存在重大差異的因素，包括在其截至 2025 年 12 月 31 日的 10-K 表格年度報告及其向證券交易委員會提交或提供的其他報告中討論的 “風險因素” 和 “管理層對財務狀況和經營結果的討論與分析” 部分。本文中的前瞻性聲明基於 Guardant Health 截至本日期的信息，Guardant Health 不承擔更新任何前瞻性聲明的義務，以反映其期望的任何變化或任何此類聲明所基於的事件、條件或情況的變化，法律要求的除外。這些前瞻性聲明不應被視為代表 Guardant Health 在本新聞稿日期之後的任何日期的觀點。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA1MTg5NzAwNDNyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA1MTg5NzAwNDNyMQ"/></p>
<p>查看商業資訊上的源版本：https://www.businesswire.com/news/home/20260518970043/en/</p>
<p><strong>投資者聯繫：</strong> Zarak Khurshid</p>
<p>investors@guardanthealth.com</p>
<p><strong>媒體聯繫：</strong> Meaghan Smithpress@guardanthealth.com</p>
<p>來源：Guardant Health, Inc.</p>

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>Guardant Health, Inc. 宣佈根據 2023 年就業誘導激勵獎勵計劃，批准 267 名新非高管員工的限制性股票單位（RSUs），總計 143,898 股。這些作為就業誘導的 RSUs 將在三年內每年歸屬一次。此舉符合納斯達克上市規則 5635(c)(4)</p>

<p>PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>加利福尼亞州帕洛阿爾託 --（商業資訊）--Guardant Health, Inc.（納斯達克：GH），一家領先的精準腫瘤學公司，今天宣佈，Guardant 董事會的薪酬委員會於 2026 年 4 月 21 日批准向 267 名新非執行員工授予代表 143,898 股普通股的限制性股票單位（“RSUs”），授予日期為 2026 年 5 月 11 日，依據 Guardant Health, Inc. 2023 年就業誘導激勵獎勵計劃（“誘導計劃”）。這些 RSUs 作為員工與 Guardant 簽訂僱傭合同的重要誘因，符合納斯達克上市規則 5635(c)(4)。</p>
</div><p>The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>誘導計劃專門用於向之前未曾是 Guardant 員工的個人授予股權獎勵，或在經過真實的非僱傭期後，作為這些個人與 Guardant 簽訂僱傭合同的重要誘因，依據納斯達克上市規則 5635(c)(4)。</p>
</div><p>One-third of the shares underlying each RSU award vest on an annual basis on the anniversary of the vesting commencement date, subject to each employee’s continued employment with Guardant as of each such vesting date. The RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a RSU award agreement covering the grant.</p>
<div class="lb-trans"><p>每個 RSU 獎勵所對應的股份三分之一將在每年授予開始日期的週年日按年歸屬，前提是每位員工在每個歸屬日期仍繼續在 Guardant 工作。這些 RSUs 受誘導計劃的條款和條件以及涵蓋該授予的 RSU 獎勵協議的條款和條件的約束。</p>
</div><p><strong>About Guardant Health</strong></p>
<div class="lb-trans"><p><strong>關於 Guardant Health</strong></p>
</div><p>Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.</p>
<div class="lb-trans"><p>Guardant Health 是一家領先的精準腫瘤學公司，專注於保護健康，讓每個人都能擁有更多無癌的時間。Guardant 成立於 2012 年，通過提供對疾病驅動因素的關鍵洞察，利用其先進的血液和組織檢測、真實世界數據和人工智能分析，正在改變患者護理並加速新的癌症療法。Guardant 的檢測有助於改善各個階段的護理結果，包括早期篩查癌症、監測早期癌症的復發以及為晚期癌症患者選擇治療方案。有關更多信息，請訪問 guardanthealth.com，並在 LinkedIn、X（推特）和 Facebook 上關注該公司。</p>
</div><p><strong>Guardant Health Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>Guardant Health 前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.</p>
<div class="lb-trans"><p>本新聞稿包含根據聯邦證券法的定義的前瞻性聲明，包括關於 Guardant Health 的液體活檢測試或檢測的潛在用途、價值、益處和優勢的聲明，這些聲明涉及風險和不確定性，可能導致實際結果與這些前瞻性聲明中表達的預期結果和期望存在重大差異。這些聲明基於當前的期望、預測和假設，實際結果可能因多種因素而與這些聲明存在重大差異。這些以及可能影響 Guardant Health 財務和運營結果的其他風險和不確定性，以及導致實際結果與本新聞稿中所作的前瞻性聲明所指示的結果存在重大差異的因素，包括在其截至 2025 年 12 月 31 日的 10-K 表格年度報告及其向證券交易委員會提交或提供的其他報告中討論的 “風險因素” 和 “管理層對財務狀況和經營結果的討論與分析” 部分。本文中的前瞻性聲明基於 Guardant Health 截至本日期的信息，Guardant Health 不承擔更新任何前瞻性聲明的義務，以反映其期望的任何變化或任何此類聲明所基於的事件、條件或情況的變化，法律要求的除外。這些前瞻性聲明不應被視為代表 Guardant Health 在本新聞稿日期之後的任何日期的觀點。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA1MTg5NzAwNDNyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260518970043r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260518970043/en/</p>
<div class="lb-trans"><p>查看商業資訊上的源版本：https://www.businesswire.com/news/home/20260518970043/en/</p>
</div><p><strong>Investor Contact:</strong> Zarak Khurshid</p>
<div class="lb-trans"><p><strong>投資者聯繫：</strong> Zarak Khurshid</p>
</div><p>investors@guardanthealth.com</p>
<div class="lb-trans"><p>investors@guardanthealth.com</p>
</div><p><strong>Media Contact:</strong> Meaghan Smithpress@guardanthealth.com</p>
<div class="lb-trans"><p><strong>媒體聯繫：</strong> Meaghan Smithpress@guardanthealth.com</p>
</div><p>Source: Guardant Health, Inc.</p>
<div class="lb-trans"><p>來源：Guardant Health, Inc.</p>
</div>

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GH Stock News

StockTitan

Guardant Health

醫藥突破 ETF - ALPS

基因免疫&健康關懷 ETF - iShares

基因改革 ETF - ARK

動態生物技術與基因組 ETF - Invesco

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 3 倍做多 - Direxion

Guardant Health 宣佈根據納斯達克上市規則 5635(c)(4) 進行激勵授予 | GH 股票新聞